Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

343 ARTÍCULOS , VIENDO DEL 271 AL 285

Primary prevention of Alzheimer's disease: is it an attainable goal?

Han JY, Han SH.

J Korean Med Sci. 2014 Jul;29(7):886-92. doi: 10.3346/jkms.2014.29.7.886. Epub 2014 Jul 11.

Inhibition of early upstream events in prodromal Alzheimer's disease by use of targeted antioxidants

Prasad KN, Bondy SC.

Curr Aging Sci. 2014;7(2):77-90. doi: 10.2174/1874609807666140804115633.

Cognitively-based methods of enhancing and maintaining functioning in those at risk of Alzheimer's disease

Hampstead BM, Mosti CB, Swirsky-Sacchetti T.

J Alzheimers Dis. 2014;42 Suppl 4:S483-93. doi: 10.3233/JAD-141476.

Auditory hallucinations associated with nitrofurantoin use: case report and review of the literature

Štuhec M.

Wien Klin Wochenschr. 2014 Sep;126(17-18):549-52. doi: 10.1007/s00508-014-0577-6. Epub 2014 Aug 15.

Beta and gamma carboline derivatives as potential anti-Alzheimer agents: A comparison

Otto R, Penzis R, Gaube F, Winckler T, Appenroth D, Fleck C, Tränkle C, Lehmann J, Enzensperger C.

Eur J Med Chem. 2014 Nov 24;87:63-70. doi: 10.1016/j.ejmech.2014.09.048. Epub 2014 Sep 16.

Efficacy of vitamins B supplementation on mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis

Li MM, Yu JT, Wang HF, Jiang T, Wang J, Meng XF, Tan CC, Wang C, Tan L.

Curr Alzheimer Res. 2014;11(9):844-52.

Feasibility and efficacy of cognitive telerehabilitation in early Alzheimer's disease: a pilot study

Jelcic N, Agostini M, Meneghello F, Bussè C, Parise S, Galano A, Tonin P, Dam M, Cagnin A.

Clin Interv Aging. 2014 Sep 24;9:1605-11. doi: 10.2147/CIA.S68145. eCollection 2014.

Reversal of cognitive decline: a novel therapeutic program

Bredesen DE.

Aging (Albany NY). 2014 Sep;6(9):707-17. doi: 10.18632/aging.100690.

[Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?]

García-Casares N, García-Arnés JA, Gómez-Huelgas R, Valdivielso-Felices P, García-Arias C, González-Santos P.

Rev Neurol. 2014 Dec 1;59(11):517-24.

Solitary living in Alzheimer's disease over 3 years: association between cognitive and functional impairment and community-based services

Wattmo C, Londos E, Minthon L.

Clin Interv Aging. 2014 Nov 14;9:1951-62. doi: 10.2147/CIA.S71709. eCollection 2014.

Searching for disease-modifying drugs in AD: can we combine neuropsychological tools with biological markers?

Caraci F, Castellano S, Salomone S, Drago F, Bosco P, Di Nuovo S.

CNS Neurol Disord Drug Targets. 2014 Feb;13(1):173-86. doi: 10.2174/18715273113129990103.

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R; Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group.

N Engl J Med. 2014 Jan 23;370(4):311-21. doi: 10.1056/NEJMoa1312889.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.

Cognitive-behavioural group therapy improves a psychophysiological marker of stress in caregivers of patients with Alzheimer's disease

Aboulafia-Brakha T, Suchecki D, Gouveia-Paulino F, Nitrini R, Ptak R.

Aging Ment Health. 2014;18(6):801-8. doi: 10.1080/13607863.2014.880406. Epub 2014 Feb 5.

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M.

J Intern Med. 2014 Mar;275(3):251-83. doi: 10.1111/joim.12191.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias